Adjuvant systemic chemotherapy with or without bevacizumab in patients with resected pulmonary metastases from colorectal cancer


Turan N., Benekli M., Dane F., Unal O. U. , Kara H. V. , Koca D., ...More

THORACIC CANCER, vol.5, no.5, pp.398-404, 2014 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 5 Issue: 5
  • Publication Date: 2014
  • Doi Number: 10.1111/1759-7714.12107
  • Journal Name: THORACIC CANCER
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Page Numbers: pp.398-404
  • Keywords: Adjuvant chemotherapy, bevacizumab, colorectal cancer, pulmonary metastasectomy, III COLON-CANCER, RANDOMIZED CONTROLLED-TRIAL, LUNG METASTASECTOMY, PHASE-III, PROGNOSTIC-FACTORS, K-RAS, BOLUS FLUOROURACIL, MUTATION STATUS, STAGE-II, OXALIPLATIN
  • Gazi University Affiliated: Yes

Abstract

Introduction: We investigated the impact of modern chemotherapy regimens and bevacizumab following pulmonary metastasectomy (PM) from metastatic colorectal cancer (CRC).